Beximco Pharmaceuticals Ltd.
BXP | IL
Overview
Corporate Details
- ISIN(s):
- US0885792061
- LEI:
- 213800IMBBD6TIOQGB56
- Country:
- Bangladesh
- Address:
- N/A
- Website:
- https://www.beximcopharma.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-13 17:10 |
Report Publication Announcement
Request of Extension to Publish Q1 Results
|
English | 11.2 KB | ||
| 2025-11-04 08:25 |
Regulatory Filings
Change of Name to Beximco Pharmaceuticals PLC.
|
English | 10.8 KB | ||
| 2025-10-27 16:53 |
Report Publication Announcement
Request of Extension to Publish Financial Results
|
English | 11.3 KB |
Automate Your Workflow. Get a real-time feed of all Beximco Pharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Beximco Pharmaceuticals Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Beximco Pharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.
South Korea
128940
South Korea
128940
A holding company managing R&D-focused pharmaceutical, API, and medical device firms.
South Korea
008930
South Korea
008930
Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.
Sweden
HNSA
Sweden
HNSA
Develops innovative therapies for rare neurological diseases, focusing on conditions like narcolepsy.
United States of America
HRMY
United States of America
HRMY
Develops branded ophthalmic therapies and custom compounded solutions for North American eyecare.
United States of America
HROW
United States of America
HROW
Developing novel immunotherapies to treat aging-related chronic inflammation.
United States of America
HCWB
United States of America
HCWB
Develops cancer therapies using its proprietary ATAC Antibody-Drug Conjugate technology.
Germany
HPHA
Germany
HPHA
Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.
United Kingdom
HEMO
United Kingdom
HEMO